The Trump administration's cancellation of NIH funding for clinical trials in cancer and other diseases could have disastrous ...

Sandy Weill on Thursday announced a new $50 million donation to create a cancer research and treatment hub focused on ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

Imagine a world where bacteria, typically feared for causing disease, are turned into powerful weapons against cancer. That’s exactly what some scientists are working on. And they are beginning to ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...

Brain cancer remains one of medicine's most formidable challenges, requiring sophisticated treatment approaches tailored to ...

Collaborative Entity Formed by Princeton University, The Rockefeller University, Weill Cornell Medicine and the Ludwig ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy ...